, Histiocytoses: Emerging neoplasia behind inflammation, vol.18, pp.113-125, 2017.
Cell(s) of origin of Langerhans cell histiocytosis, Hematol Oncol Clin North Am, vol.29, pp.825-838, 2015. ,
Langerhans cell histiocytosis: Therapeutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of age, Br J Haematol, vol.174, pp.887-898, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01331987
Response to initial treatment of multisystem Langerhans cell histiocytosis: An important prognostic indicator, Med Pediatr Oncol, vol.39, pp.581-585, 2002. ,
Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: Results of an international phase 2 study, Blood, vol.126, pp.1415-1423, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01231424
Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: Outcome by intensity of conditioning, Br J Haematol, vol.169, pp.711-718, 2015. ,
BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to first-line therapy, J Clin Oncol, vol.34, pp.3023-3030, 2016. ,
Treatment of BRAF-mutant melanoma: The role of vemurafenib and other therapies, Clin Pharmacol Ther, vol.95, pp.24-31, 2014. ,
Vemurafenib use in an infant for high-risk Langerhans cell histiocytosis, JAMA Oncol, vol.1, pp.836-838, 2015. ,
Targeted inhibition of the MAPK pathway: Emerging salvage option for progressive life-threatening multisystem LCH, Blood Adv, vol.1, pp.352-356, 2017. ,
, European Medicines Agency: Orphan drug designation. Committee for Orphan Medicinal Products 313647, European Medicines Agency, 2016.
Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years, Pediatr Blood Cancer, vol.60, pp.175-184, 2013. ,
Vemurafenib in Langerhans cell histiocytosis: Report of a pediatric patient and review of the literature, Oncotarget, vol.9, pp.22236-22240, 2018. ,
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages, Blood, vol.127, pp.2672-2681, 2016. ,
Cholestasis, sclerosing cholangitis, and liver transplantation in Langerhans cell histiocytosis, Med Pediatr Oncol, vol.38, pp.178-182, 2002. ,
Central nervous system disease in Langerhans cell histiocytosis, J Pediatr, vol.156, pp.873-881, 2010. ,
Long term morbidity and health related quality of life after multi-system Langerhans cell histiocytosis, Eur J Cancer, vol.42, pp.2563-2569, 2006. ,
A new clinical score for disease activity in Langerhans cell histiocytosis, Pediatr Blood Cancer, vol.43, pp.770-776, 2004. ,
Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification, Blood, vol.111, pp.2556-2562, 2008. ,
Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis, Blood, vol.121, pp.5006-5014, 2013. ,
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), Eur J Cancer, vol.45, pp.228-247, 2009. ,
A LC/MS/MS micro-method for human plasma quantification of vemurafenib. Application to treated melanoma patients, J Pharm Biomed Anal, vol.97, pp.29-32, 2014. ,
Circulating cell-free BRAF V600E as a biomarker in children with Langerhans cell histiocytosis, Br J Haematol, vol.178, pp.457-467, 2017. ,
Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients, Clin Chem, vol.59, pp.1722-1731, 2013. ,
URL : https://hal.archives-ouvertes.fr/inserm-02299581
Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults, Blood, vol.130, pp.167-175, 2017. ,
A randomized trial of treatment for multisystem Langerhans' cell histiocytosis, J Pediatr, vol.138, pp.728-734, 2001. ,
-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH), Pediatr Blood Cancer, vol.53, issue.2, pp.1271-1276, 2009. ,
Clinical responses and persistent BRAF V600E + blood cells in children with LCH treated with MAPK pathway inhibition, Blood, vol.133, pp.1691-1694, 2019. ,
Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: A study of 42 patients, Ann Oncol, vol.24, pp.1691-1697, 2013. ,
Severe adverse events from the treatment of advanced melanoma: A systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2, J Dermatolog Treat, vol.25, pp.401-408, 2014. ,